CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Income Statement [Abstract]
Revenue	$ 3,768	$ 42	$ 9,040	$ 63
Cost of revenue	4,423	14,235	11,495	26,483
Gross margin	(655)	(14,193)	(2,455)	(26,420)
Operating expenses:
Research and development	29,065	16,553	77,853	40,302
Selling, general and administrative	20,884	16,688	40,432	43,962
Impairment of equipment	0	4,411	0	4,411
Restructuring cost	38,146	0	38,146	0
Total operating expenses	88,095	37,652	156,431	88,675
Loss from operations	(88,750)	(51,845)	(158,886)	(115,095)
Other income (expense):
Change in fair value of common stock warrants	(33,660)	(14,340)	(12,540)	(27,180)
Interest income	3,326	3,150	6,886	5,616
Interest expense	(1,691)	(1,270)	(3,350)	(1,270)
Other income (loss), net	242	(1)	708	20
Total other expense, net	(31,783)	(12,461)	(8,296)	(22,814)
Loss before income tax benefit	(120,533)	(64,306)	(167,182)	(137,909)
Income tax benefit	(4,586)	0	(4,738)	0
Net loss	(115,947)	(64,306)	(162,444)	(137,909)
Net loss attributable to non-controlling interests	(75)	0	(204)	0
Net loss attributable to Enovix	$ (115,872)	$ (64,306)	$ (162,240)	$ (137,909)
Net loss per share attributable to Enovix shareholders, basic (in dollars per share)	$ (0.67)	$ (0.41)	$ (0.95)	$ (0.88)
Net loss per share attributable to Enovix shareholders, diluted (in dollars per share)	$ (0.67)	$ (0.41)	$ (0.95)	$ (0.88)
Weighted average number of common shares outstanding, basic (in shares)	172,399,172	157,151,386	170,272,069	156,397,145
Weighted average number of common shares outstanding, diluted (in shares)	172,399,172	157,151,386	170,272,069	156,397,145